Research Use Only
BPC-157 vs TB-500
Neutral RUO comparison of BPC-157 and TB-500 using public protocol-library fields: vial size, research class, mechanism, evidence level and references.
Public fields onlyReferences included
This page compares only public, research-context fields from the AllPeptides protocol library. It is not a ranking, recommendation, safety comparison or human-use guide.
Public research comparison fields
| Field | BPC-157 | TB-500 |
|---|---|---|
| Name | BPC-157 | TB-500 |
| Representative vial size | 2mg | 2mg |
| Research class | Recovery / tissue research | Recovery / tissue research |
| Mechanism context | BPC-157 modulates nitric oxide pathways and growth factor expression to support angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of gut, tendon, ligament and muscle injuries. | TB-500 interacts with actin to regulate cell migration, stem cell differentiation and the inflammatory response. Preclinical studies show improved healing of skin, tendon and cardiac tissue. |
| Evidence level | Not specified in profile | Not specified in profile |
Combined references
- Journal of Pharmacological Sciences — BPC-157 promotes healing through regulation of the NO system
View source - Pharmaceuticals (MDPI) — Multifunctionality of BPC-157 (2025)
View source - Sikiric P et al. Curr Neuropharmacol 2016 — BPC-157 stable gastric pentadecapeptide
View source - Ehrlich HP et al. Ann N Y Acad Sci 2010 — Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts.
View source - Biçer O et al. Jt Dis Relat Surg 2026 — Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
View source